Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection

ClinicalTrials.gov ID: NCT00606086

Public ClinicalTrials.gov record NCT00606086. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 8, 2026, 3:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Randomized, Open Label, Multi-center, Therapeutic Trial of the Efficacy, Immunogenicity, and Safety of GI-5005; an Inactivated Recombinant Saccharomyces Cerevisiae Expressing a Hepatitis C Virus NS3-Core Fusion Protein, Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone, and GI-5005 Salvage of Standard of Care Failures, in Patients With Genotype 1 Chronic Hepatitis C Infection

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The GI-5005 therapeutic vaccine in combination with standard of care or standard of care alone will be injected under the skin of HCV subjects. Patients will be monitored for safety, immune responses and any therapeutic benefits related to the injections including EVR, ETR, and SVR.

Study identification

NCT ID
NCT00606086
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
GlobeImmune
Industry
Enrollment
140 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2007
Primary completion
Oct 31, 2012
Completion
Oct 31, 2012
Last update posted
Jun 26, 2014

2007 – 2012

United States locations

U.S. sites
25
U.S. states
18
U.S. cities
24
Facility City State ZIP Site status
University of Alabama Birmingham Birmingham Alabama 35294
University of Arizona Tucson Arizona 85724
Scripps Clinic Torrey Pines La Jolla California 92037
Research and Education inc. San Diego California 92105
University of Colorado Aurora Colorado 80045
South Denver Gastroenterology Englewood Colorado 80113
University of Connecticut Health Center Farmingtom Connecticut 06030
Yale University School of Medicine New Haven Connecticut 06520
NW Georgia Research Institute Marietta Georgia 30060
Hawaii Medical Center Honolulu Hawaii 96817
Northwest Indiana Center for Clinical Research Valparaiso Indiana 46383
Tulane University Hospital New Orleans Louisiana
Maryland Digestive Disease Research Laurel Maryland 20707
Henry Ford Health System Detroit Michigan 48202
Mayo Clinic Rochester Minnesota 55905
Gastroenterology Associates, PA Jackson Mississippi 39202
St. Louis University St Louis Missouri 63104
Weill Medical College of Cornell University New York New York 10021
Columbia University New York New York 10032
Duke University Durham North Carolina 27710
University of Texas Southwestern Medical Center at Dallas Dallas Texas 75390
Baylor College of Medicine Houston Texas 77030
Alamo Medical Research San Antonio Texas 78215
Liver Institute of Virginia Bon Secours Health System Newport News Virginia 23602
McGuire VA Medical Center Richmond Virginia 23249

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00606086, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 26, 2014 · Synced Sep 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00606086 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →